NZ704660A - Process for making isoquinoline compounds - Google Patents

Process for making isoquinoline compounds

Info

Publication number
NZ704660A
NZ704660A NZ704660A NZ70466013A NZ704660A NZ 704660 A NZ704660 A NZ 704660A NZ 704660 A NZ704660 A NZ 704660A NZ 70466013 A NZ70466013 A NZ 70466013A NZ 704660 A NZ704660 A NZ 704660A
Authority
NZ
New Zealand
Prior art keywords
compounds
isoquinoline compounds
making
making isoquinoline
hif
Prior art date
Application number
NZ704660A
Other languages
English (en)
Inventor
Michael D Thompson
Jung Min Park
Michael P Arend
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48857024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ704660(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of NZ704660A publication Critical patent/NZ704660A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Epidemiology (AREA)
NZ704660A 2012-07-16 2013-07-15 Process for making isoquinoline compounds NZ704660A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261672191P 2012-07-16 2012-07-16
PCT/US2013/050538 WO2014014834A1 (en) 2012-07-16 2013-07-15 Process for making isoquinoline compounds

Publications (1)

Publication Number Publication Date
NZ704660A true NZ704660A (en) 2017-10-27

Family

ID=48857024

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ704660A NZ704660A (en) 2012-07-16 2013-07-15 Process for making isoquinoline compounds

Country Status (22)

Country Link
US (2) US9340511B2 (enExample)
EP (2) EP3219706A1 (enExample)
JP (1) JP6196671B2 (enExample)
KR (1) KR102145272B1 (enExample)
CN (2) CN103435546B (enExample)
AU (1) AU2013290437B2 (enExample)
BR (1) BR112015001106B1 (enExample)
CA (1) CA2879238C (enExample)
CY (1) CY2022018I1 (enExample)
DK (1) DK2872487T3 (enExample)
ES (1) ES2631655T3 (enExample)
HU (2) HUE034409T2 (enExample)
IL (1) IL236625B (enExample)
IN (1) IN2015KN00265A (enExample)
MX (1) MX350922B (enExample)
MY (1) MY171483A (enExample)
NZ (1) NZ704660A (enExample)
PL (1) PL2872487T3 (enExample)
PT (1) PT2872487T (enExample)
SG (1) SG11201500234YA (enExample)
WO (1) WO2014014834A1 (enExample)
ZA (1) ZA201500664B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100932169B1 (ko) 2003-06-06 2009-12-16 피브로겐, 인크. 질소-함유 헤테로아릴 화합물 및 내인성 적혈구생성소의증가에서의 그들의 사용
CN102272117B (zh) 2008-11-14 2015-06-17 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
US9115085B2 (en) * 2012-07-16 2015-08-25 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
US9340511B2 (en) * 2012-07-16 2016-05-17 Fibrogen, Inc. Process for making isoquinoline compounds
IL296484B2 (en) 2013-06-06 2025-03-01 Fibrogen Inc Pharmaceutical formulations of HIF hydroxylase inhibitor
CN103694172A (zh) * 2013-12-26 2014-04-02 辽宁亿灵科创生物医药科技有限公司 含氮杂芳基化合物的衍生物
WO2016034108A1 (zh) 2014-09-02 2016-03-10 广东东阳光药业有限公司 喹啉酮类化合物及其应用
WO2016045125A1 (en) * 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
CN104447547B (zh) * 2014-11-10 2017-04-19 苏州康润医药有限公司 4‑氨基异喹啉‑8‑甲酸甲酯的合成方法
CN106146490B (zh) * 2015-03-27 2018-10-23 沈阳三生制药有限责任公司 被芳氧基或杂芳氧基取代的5-羟基-1,7-萘啶化合物、其制备方法及其制药用途
CN104892509B (zh) * 2015-06-04 2018-03-09 苏州明锐医药科技有限公司 诺得司他的制备方法
CN106187888A (zh) * 2016-07-18 2016-12-07 江苏德源药业股份有限公司 Fg‑4592单晶及其制备方法
CN106478503A (zh) * 2016-09-29 2017-03-08 上海勋和医药科技有限公司 Roxadustat中间体的制备方法
CZ2016627A3 (cs) 2016-10-07 2018-04-18 Zentiva, K.S. Způsob přípravy (7-fenoxy-4-hydroxy-1-methylisochinolin-3-karbonyl)glycinu (roxadustatu) a jeho intermediátů založený na souběžném otevírání oxazolového kruhu, štěpení etheru a tvorbě iminu
CN107954931B (zh) * 2016-10-17 2021-06-22 上海医药集团青岛国风药业股份有限公司 一种诺得司他的制备方法
WO2018140186A1 (en) 2017-01-28 2018-08-02 Kingchem Life Science Llc A process for preparing 5-phenoxy-1(3h)isobenzofuranone
WO2019106621A1 (en) * 2017-12-01 2019-06-06 Dr. Reddy's Laboratories Limited Process for the preparation of roxadustat and its intermediates
CN109956870A (zh) 2017-12-14 2019-07-02 南京卡文迪许生物工程技术有限公司 一种罗沙司他的合成方法及其中间体化合物
CN110218184B (zh) * 2018-03-01 2022-09-27 广东东阳光药业有限公司 诺德司他共晶及其制备方法
WO2019174631A1 (zh) * 2018-03-16 2019-09-19 上海医药集团股份有限公司 一种诺得司他的制备方法
CN110526813B (zh) * 2018-05-24 2022-06-28 杭州科巢生物科技有限公司 异喹啉化合物的制备方法及其中间体
CN111978226B (zh) 2018-06-05 2022-03-04 沈阳化工大学 一种三氟乙基硫醚（亚砜）取代苯类化合物及其用途
AU2019375983A1 (en) 2018-11-09 2021-06-10 Vivace Therapeutics, Inc. Bicyclic compounds
CN109776415B (zh) * 2019-03-07 2020-11-17 福建南方制药股份有限公司 一种Roxadustat中间体的制备方法
IL287222B2 (en) 2019-04-16 2025-04-01 Vivace Therapeutics Inc Bicyclic compounds
RU2709493C1 (ru) * 2019-08-01 2019-12-18 Марат Феликсович Фазылов Способ получения роксадустата
EP4010318A1 (en) * 2019-08-07 2022-06-15 Teva Pharmaceuticals International GmbH Processes for the preparation of roxadustat and intermediates thereof
CN112441975B (zh) * 2019-09-03 2023-10-31 西藏嘉信景天药业有限公司 一种罗沙司他重要中间体的制备方法
CN112679431B (zh) * 2019-10-18 2023-05-05 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
US20230112619A1 (en) * 2019-10-18 2023-04-13 Shanghai Desano Chemical Pharmaceutical Co., Ltd. Method for preparing isoquinolinone compounds
CN112679430B (zh) * 2019-10-18 2023-05-05 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
US12612367B2 (en) 2019-12-10 2026-04-28 Akebia Therapeutics, Inc. Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
CN113444042A (zh) * 2020-03-27 2021-09-28 南京海润医药有限公司 一种罗沙司他的制备方法
CN115867537A (zh) * 2020-04-21 2023-03-28 迈兰实验室有限公司 改进的罗沙司他的制备方法
CN111533691A (zh) * 2020-06-08 2020-08-14 重庆三圣实业股份有限公司 一种罗沙司他的制备方法
CN113801060B (zh) * 2020-06-13 2025-06-27 苏州鹏旭医药科技有限公司 一种多取代异喹啉化合物的制备方法
WO2021254469A1 (zh) * 2020-06-19 2021-12-23 济川(上海)医学科技有限公司 一种罗沙司他及其中间体的合成方法和其中间体
CN112409258B (zh) * 2020-11-20 2025-11-25 杭州科巢生物科技有限公司 一种罗沙司他的制备方法
CN114644589A (zh) * 2020-12-17 2022-06-21 鲁南制药集团股份有限公司 一种化合物n-[（4-羟基--1-甲基-3-异喹啉基）羰基]-甘氨酸的制备方法
CN114671807B (zh) * 2020-12-24 2026-03-24 联化科技（德州）有限公司 一种1-取代异喹啉类化合物的制备方法
US20230101768A1 (en) * 2021-08-13 2023-03-30 The Board Of Regents Of The University Of Texas System Method to treat manganese toxicity and manganese-induced parkinsonism in humans
CN116178260A (zh) * 2021-11-26 2023-05-30 四川国康药业有限公司 一种治疗肾性贫血的化合物及其制备方法
CN115124467A (zh) * 2022-07-11 2022-09-30 天津力生制药股份有限公司 一种罗沙司他关键中间体的制备方法
CN117105862B (zh) * 2023-07-26 2025-12-30 北京福元医药股份有限公司 一种罗沙司他及其中间体的制备方法
CN117486797A (zh) * 2023-11-23 2024-02-02 传健生物医药(厦门)有限公司 一种罗沙司他关键中间体及罗沙司他的制备方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036964A (en) 1973-10-11 1977-07-19 Beecham Group Limited Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis
US3989704A (en) 1973-10-30 1976-11-02 Sandoz, Inc. 3-Substituted-4-aryl isoquinolines
DE2818423A1 (de) 1978-04-27 1979-11-08 Hoechst Ag Neue isochinolinderivate und verfahren zu ihrer herstellung
DE3233424A1 (de) 1982-09-09 1984-03-15 Hoechst Ag, 6230 Frankfurt Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4558006A (en) 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US4559403A (en) 1983-05-19 1985-12-17 Hoffmann-La Roche Inc. Substituted isoquinolines
US4584379A (en) 1985-01-22 1986-04-22 Merrell Dow Pharmaceuticals Inc. Isoquinoline thromboxane synthetase inhibitors
US4667016A (en) 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US4822800A (en) 1986-06-09 1989-04-18 Ortho Pharmaceutical Corporation Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US4952588A (en) 1987-11-27 1990-08-28 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides
US4966906A (en) 1987-11-27 1990-10-30 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-isoquinolinecarboxamides
EP0650960B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
ATE149486T1 (de) 1993-11-02 1997-03-15 Hoechst Ag Substituierte heterocyclische carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
AU4515696A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
WO1998023608A1 (en) 1996-11-27 1998-06-04 Dupont Pharmaceuticals Company Novel integrin receptor antagonists
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2779963A1 (fr) 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
IT1320162B1 (it) 2000-02-09 2003-11-18 Rotta Research Lab Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
WO2002074981A2 (en) 2001-03-21 2002-09-26 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
GB0107901D0 (en) * 2001-03-29 2001-05-23 Cyclacel Ltd Anti-cancer compounds
WO2002100832A1 (en) 2001-06-13 2002-12-19 Genesoft Pharmaceuticals, Inc. Isoquinoline compounds having antiinfective activity
WO2002101073A2 (en) 2001-06-13 2002-12-19 Genesoft Pharmaceuticals, Inc. Aryl-benzimidazole compounds having antiinfective activity
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
CN102526045A (zh) 2001-12-06 2012-07-04 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
US8318703B2 (en) 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
WO2005007192A2 (en) 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
KR100932169B1 (ko) 2003-06-06 2009-12-16 피브로겐, 인크. 질소-함유 헤테로아릴 화합물 및 내인성 적혈구생성소의증가에서의 그들의 사용
CA2532064A1 (en) 2003-07-15 2005-02-03 Merck & Co., Inc. Hydroxypyridine cgrp receptor antagonists
EP1658074B1 (en) 2003-08-01 2012-11-07 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
WO2005014533A2 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
AU2005250412B2 (en) 2004-05-28 2009-09-17 Fibrogen, Inc. HIF prolyl hydroxylase activity assay
AP2007004047A0 (en) * 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
CN101166745A (zh) 2005-03-02 2008-04-23 菲布罗根有限公司 噻吩并吡啶化合物和其使用方法
US20060276477A1 (en) 2005-06-06 2006-12-07 Fibrogen, Inc. Treatment method for anemia
ATE470439T1 (de) 2005-06-15 2010-06-15 Fibrogen Inc Verwendung von hif 1alfa modulatoren zur behandlung von krebs
US7937393B2 (en) 2005-11-28 2011-05-03 Commvault Systems, Inc. Systems and methods for classifying and transferring information in a storage network
WO2007090068A2 (en) 2006-01-27 2007-08-09 Fibrogen, Inc. Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif)
KR20080097446A (ko) 2006-02-16 2008-11-05 피브로겐, 인크. 뇌졸중의 치료를 위한 화합물과 방법
EP2016078B1 (en) 2006-04-04 2016-06-15 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as hif modulators
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
US8217043B2 (en) 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
CN102272117B (zh) 2008-11-14 2015-06-17 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
CN103429239A (zh) 2011-01-13 2013-12-04 菲布罗根有限公司 增加网织红细胞血红蛋白含量的方法
CN103608346B (zh) 2011-02-02 2016-06-15 菲布罗根有限公司 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物
CA2842730C (en) 2011-07-22 2018-08-21 Beijing Betta Pharmaceuticals Co., Ltd Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
SG11201405574UA (en) 2012-03-09 2014-10-30 Fibrogen Inc 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
US9115085B2 (en) 2012-07-16 2015-08-25 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
US9340511B2 (en) * 2012-07-16 2016-05-17 Fibrogen, Inc. Process for making isoquinoline compounds
WO2014116849A1 (en) 2013-01-24 2014-07-31 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
IL296484B2 (en) 2013-06-06 2025-03-01 Fibrogen Inc Pharmaceutical formulations of HIF hydroxylase inhibitor

Also Published As

Publication number Publication date
EP2872487B1 (en) 2017-04-26
KR20150058147A (ko) 2015-05-28
CN103435546A (zh) 2013-12-11
JP6196671B2 (ja) 2017-09-13
AU2013290437A1 (en) 2015-02-19
CY2022018I2 (el) 2023-01-05
IN2015KN00265A (enExample) 2015-06-12
MX2015000505A (es) 2015-07-17
EP3219706A1 (en) 2017-09-20
DK2872487T3 (en) 2017-06-06
KR102145272B1 (ko) 2020-08-18
PT2872487T (pt) 2017-05-15
US9708269B2 (en) 2017-07-18
CN103435546B (zh) 2016-08-10
EP2872487A1 (en) 2015-05-20
BR112015001106A2 (pt) 2017-06-27
AU2013290437B2 (en) 2017-11-02
BR112015001106B1 (pt) 2021-11-09
MX350922B (es) 2017-09-25
CA2879238A1 (en) 2014-01-23
PL2872487T3 (pl) 2017-09-29
ES2631655T3 (es) 2017-09-01
CA2879238C (en) 2021-08-10
HUS2200030I1 (hu) 2022-07-28
HUE034409T2 (en) 2018-02-28
US20160194285A1 (en) 2016-07-07
CY2022018I1 (el) 2023-01-05
SG11201500234YA (en) 2015-02-27
WO2014014834A1 (en) 2014-01-23
CN106083719B (zh) 2019-10-18
US9340511B2 (en) 2016-05-17
JP2015524409A (ja) 2015-08-24
IL236625A0 (en) 2015-02-26
US20150175550A1 (en) 2015-06-25
MY171483A (en) 2019-10-15
CN106083719A (zh) 2016-11-09
ZA201500664B (en) 2017-08-30
IL236625B (en) 2019-01-31

Similar Documents

Publication Publication Date Title
MX350922B (es) Proceso para elaborar compuestos de isoquinolina.
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
WO2017064566A3 (en) Inducible modification of a cell genome
MY203474A (en) Substituted tricyclic compounds as fgfr inhibitors
IN2015DN02793A (enExample)
WO2014124087A8 (en) Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
MX2015005944A (es) Cepas microbianas, composiciones y metodos para incrementar el fosfato disponible para las plantas.
MY195343A (en) A Novel Phtalazinone Derivatives and Manufacturing Process Thereof
MX347882B (es) Procedimiento mejorado para preparar (3e, 7e)-homofarnesol.
WO2014086982A3 (en) Stable metal compounds, their compositions and methods of their use
JO3722B1 (ar) مثبطات 6-(5- هيدروكسي-1h- بيرازول-1- يل) و مشتقات نيكوتيناميد واستخدامها كمثبطات
EP4582090A3 (en) Composition comprising pegylated arginine deiminase
MX2020002544A (es) Sales de glicopirrolato.
MY197129A (en) Electrochemical coupling of two phenols which differ in their oxidation potential
GB201205769D0 (en) Methods for preparing samples for nucleic acid amplification
WO2014015210A3 (en) Microorganisms and processes for the conversion of glycerol to isoprene
PH12014501991B1 (en) Phenicol antibacterials
AU2014230812A8 (en) Process for making benzoxazepin compounds
MX2011013878A (es) 4-hidroxipirimidina-5-carboxamidas sustituidas.
WO2013168176A3 (en) Process for preparation of fosaprepitant and salt thereof
MX2015016603A (es) Composiciones de corticosteroides.
MX2013005954A (es) Compuestos intermedios y procesos para la preparacion de derivados de quinolina tal como laquinimod sodico.
MX2011013879A (es) 4-hidroxipirimidina-5-carboxamidas sustituidas.
IN2014DN10135A (enExample)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2019 BY CPA GLOBAL

Effective date: 20180607

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2020 BY TIA WOOSNAM

Effective date: 20190715

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2021 BY CPA GLOBAL

Effective date: 20200625

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2022 BY CPA GLOBAL

Effective date: 20210603

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2023 BY CPA GLOBAL

Effective date: 20220607

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2024 BY ANAQUA SERVICES

Effective date: 20230621

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2025 BY ANAQUA SERVICES

Effective date: 20240619

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2026 BY ANAQUA SERVICES

Effective date: 20250731